Asia Deal Watch: Athenex Changes Mind, Gets Back Chinese Rights To Actinic Keratosis Candidate
Executive SummaryFollowing a positive Phase III data readout for KX2-391, Athenex requests dissolution of its recent deal conferring rights to the drug in China to Chongqing Jingdong Junzhuo. TaiwanJ licenses Asian rights outside its home market for JK-122 to Newsoara.
You may also be interested in...
Shionogi has become the latest Japanese company to build its presence in the digital health realm, this time through an alliance with Akili for two novel digital therapeutics.